Joshua Zeidner

Has grant

Associate Professor of Medicine

University of North Carolina, Lineberger Comprehensive Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Targeting Regulatory T Cells During Lymphocyte Recovery in Newly Diagnosed Acute Myeloid Leukemia (AML)

Open Date: 2014-07-01

Close Date: 2017-06-01

Articles (10)

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (7)

María Díez Campelo

Universidad de Salamanca

SPAIN

View details

Jordi Esteve Reyner

Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

SPAIN

View details

David Bearss

UNITED STATES

View details

Thomas B. Alexander

UNITED STATES

View details

Benjamin G. Vincent

University of North Carolina at Chapel Hill

UNITED STATES

View details

Nathan Montgomery

Assistant Professor

University of North Carolina

UNITED STATES

View details

Eric Weimer

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Joshua Zeidner

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (10)

A reappraisal of ASXL1 mutation sites and the cohesin-binding motif in myeloid disease

TP53 or Not TP53: That Is the Question

The development of pevonedistat in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): hope or hype?

Bilineal evolution of a U2AF1-mutated clone associated with acquisition of distinct secondary mutations

Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after enasidenib treatment

Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML

Emerging therapies for AML with myelodysplasia-related changes: slowly but surely moving the needle

Collaborators (7)

María Díez Campelo

Jordi Esteve Reyner

David Bearss

Thomas B. Alexander

Benjamin G. Vincent

Nathan Montgomery

Eric Weimer

Make your next move.